The stock of Immunomedics, Inc. (NASDAQ:IMMU) is a huge mover today! About 20.05 million shares traded hands or 2318.91% up from the average. Immunomedics, Inc. (NASDAQ:IMMU) has risen 34.43% since March 2, 2016 and is uptrending. It has outperformed by 26.17% the S&P500.
The move comes after 7 months negative chart setup for the $237.49M company. It was reported on Oct, 5 by Barchart.com. We have $2.20 PT which if reached, will make NASDAQ:IMMU worth $28.50 million less.
Immunomedics, Inc. (NASDAQ:IMMU) Ratings Coverage
Out of 2 analysts covering Immunomedics (NASDAQ:IMMU), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. Immunomedics has been the topic of 5 analyst reports since July 29, 2015 according to StockzIntelligence Inc. The firm has “Hold” rating by Jefferies given on Wednesday, July 29. The company was downgraded on Friday, December 4 by Wells Fargo. The firm earned “Hold” rating on Tuesday, March 15 by Jefferies. Jefferies upgraded the shares of IMMU in a report on Friday, May 6 to “Buy” rating. The stock has “Market Perform” rating given by Wells Fargo on Tuesday, June 21.
According to Zacks Investment Research, “Immunomedics Inc. is a New Jersey-based biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. They have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create highly targeted agents. Using these technologies, the company have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. They have recently licensed its lead product candidate, epratuzumab, to UCB, S.A. for the treatment of all autoimmune disease indications worldwide.”
Insitutional Activity: The institutional sentiment decreased to 1.02 in Q2 2016. Its down 0.09, from 1.11 in 2016Q1. The ratio worsened, as 14 funds sold all Immunomedics, Inc. shares owned while 34 reduced positions. 27 funds bought stakes while 22 increased positions. They now own 50.90 million shares or 5.47% more from 48.26 million shares in 2016Q1.
Moreover, Renaissance Technologies Lc has 0.01% invested in Immunomedics, Inc. (NASDAQ:IMMU) for 1.77M shares. Deutsche Financial Bank Ag reported 959,171 shares or 0% of all its holdings. Sabby Mgmt Ltd Llc accumulated 425,000 shares or 0.05% of the stock. Teacher Retirement System Of Texas last reported 12,582 shares in the company. Bancorp Of Montreal Can holds 0% or 440 shares in its portfolio. Moreover, D E Shaw & Inc has 0% invested in Immunomedics, Inc. (NASDAQ:IMMU) for 18,800 shares. Cambridge Research Advisors has 10,800 shares for 0% of their US portfolio. Tiaa Cref Management Ltd Liability owns 386,678 shares or 0% of their US portfolio. The Florida-based Raymond James Fincl has invested 0% in Immunomedics, Inc. (NASDAQ:IMMU). Oppenheimer And has invested 0% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU). Orbimed Advsr Limited Liability Company last reported 3.80M shares in the company. California Pub Employees Retirement Sys has invested 0% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU). National Bank Of America Corporation De, a North Carolina-based fund reported 20,396 shares. Boston Private Wealth Limited Liability holds 0.01% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU) for 145,000 shares. Blackrock Institutional Na last reported 2.68 million shares in the company.
Insider Transactions: Since June 6, 2016, the stock had 0 buys, and 7 selling transactions for $5.11 million net activity. GOLDENBERG CYNTHIA L had sold 371,990 shares worth $1.13 million on Friday, June 10. Stark Don C sold $29,451 worth of Immunomedics, Inc. (NASDAQ:IMMU) on Wednesday, August 24. $1.37M worth of Immunomedics, Inc. (NASDAQ:IMMU) was sold by GOLDENBERG DAVID M on Monday, June 6. PAETZOLD MARY E also sold $44,673 worth of Immunomedics, Inc. (NASDAQ:IMMU) shares. MARKISON BRIAN A also sold $44,634 worth of Immunomedics, Inc. (NASDAQ:IMMU) shares.
More important recent Immunomedics, Inc. (NASDAQ:IMMU) news were published by: 247Wallst.com which released: “Immunomedics Falls Sharply on Secondary Offering” on October 05, 2016, also Fool.com published article titled: “Immunomedics Inc. Gets Tripped Up by a Formality”, Nasdaq.com published: “Earnings Reaction History: Immunomedics Inc., 100.0% Follow-Through Indicator …” on August 17, 2016. More interesting news about Immunomedics, Inc. (NASDAQ:IMMU) was released by: Investorplace.com and their article: “Why SouFun Holdings Ltd (SFUN), Citigroup Inc (C) and Immunomedics, Inc. (IMMU …” with publication date: June 03, 2016.
IMMU Company Profile
Immunomedics, Inc., incorporated on July 6, 1982, is a clinical-stage biopharmaceutical company, which is engaged in researching, developing, manufacturing and marketing biopharmaceutical products. It develops monoclonal antibody products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. The Company’s geographic divisions include United States and Europe. The Company’s technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. As of June 30, 2016, the Company had a pipeline of eight clinical-stage product candidates. The Company’s portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while managing the overall toxic effects that are found with conventional administration of these chemotherapy agents. The Company, as part of a research collaboration, is focused on studying epratuzumab as a thorium-227-labeled antibody. The Firm also has a range of other product candidates that target solid tumors and hematologic malignancies, as well as other diseases, in various-stages of clinical and pre-clinical development. These include combination therapies involving antibody-drug conjugates, bispecific antibodies targeting cancers and infectious diseases as T-cell redirecting immunotherapies, as well as bispecific antibodies for next-generation cancer and autoimmune disease therapies, created using its DOCK-AND-LOCK (DNL) protein conjugation technology.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.